Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Financing › Details

Hemotune–SEVERAL: investment, 202403 financing round Series B2 CHF14m led by Belmondo

 

Period Period 2024-03-25
Organisations Money taker Hemotune AG
  Money source SEVERAL
Products Product HemoSystem (blood purification platform based on nanoengineered magnetic beads)
  Product 2 venture capital
Person Person Barra, Cédric (Occident Group 201808 Investment Manager)
     

Hemotune AG. (3/25/24). "Press Release: Hemotune Raises CHF 14 Million Series B2 Funding for Clinical Trials with the HemoSystem". Schlieren.

hemotune AG, a pioneering Swiss biotech company, today announced the successful closing of a CHF 14 million Series B2 round dedicated to advancing its HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads. The investment was led by Belmondo with continued support of existing investors including VP Venture Partners, HEMEX, OCCIDENT, Zürcher Kantonalbank, and joined by EFI.

The Series B2 funding round represents a significant step forward for hemotune, following the successful completion of preclinical development for their HemoSystem blood purification platform. This substantial investment will now allow the platform to move into clinical trials, marking a crucial phase in its development.

The HemoSystem stands out for its ability to effectively remove large biomolecules directly from patients' bloodstreams, offering a unique approach to implement precision medicine multi-target treatments which would not be possible through drugs. Initially focusing on treating sepsis-related immune suppression, hemotune also plans to explore other potential uses for the platform in the future. Given the serious impact of sepsis, which leads to around 11 million deaths annually and is a major economic burden, the potential benefits of this innovative technology are significant for patients and healthcare systems alike.

Lukas Langenegger, CEO and co-founder of hemotune AG, states: "I am immensely proud of our team’s achievements in concluding the preclinical development of the HemoSystem. As we navigate through a challenging fundraising climate, the success of our Series B2 funding round underscores not only the potential of our innovative blood purification platform but also the confidence our backers have in our team and vision to revolutionize medical treatment."

Dr. Darius Madjdpour, founder at Belmondo comments: "The team of hemotune, through an impressive performance over the last 7 years, has managed to develop one of the most promising platform technologies I have seen in medicine. The possibilities to tackle various diseases and enabling therapies through HemoSystem has convinced us to take the lead in this funding round. We are happy to support the team for further journey and will be excited to see the product spread globally and help many patients over the coming years."

Cédric Barra, Senior Investment Manager at OCCIDENT: “This Series B2 funding will now pave the way for clinical trials. The company has done an excellent job over the last few years to get to this point and we hope that hemotune can make the therapy available to patients soon.”

Dr. Annick Bay, Senior Associate of VP Venture Partners adds: ”hemotune’s precision blood purification system is designed to specifically remove individual proteins or combinations thereof, resulting in a medical device platform more akin to therapeutics developed by a traditional biotech, with the added benefit of a leaner development pathway for individual indications.”

Pascal Winnen, CEO of HEMEX, asserts: "With our established expertise as a CRO in managing global infectious disease clinical trials, we are deeply committed to hemotune's pioneering strategy for combating septic shock. We recognize the potential for broader applications of their technology to selectively filter harmful agents from the bloodstream. Our team is eager to provide robust support to hemotune throughout the clinical phase of their development program. Our ultimate aim is to facilitate the worldwide availability of the innovative HemoSystem for patients in need."

   
Record changed: 2024-04-04

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Hemotune AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x300px




» top